

REPORT 5 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (A-09)
The Use of Hormones for “Antiaging”: A Review of Efficacy and Safety
(Reference Committee E)

EXECUTIVE SUMMARY

Objective: This report reviews the scientific evidence on the benefits and risks of human growth hormone (hGH), dehydroepiandrosterone (DHEA), testosterone, and estrogens with or without progestins as supplements to prevent, slow, or reverse age-related changes in otherwise healthy adults.

Methods: Four MEDLINE searches were conducted using the MESH terms “human growth hormone” AND “aging,” “dehydroepiandrosterone” AND “aging,” “testosterone” AND “aging,” and “estrogens” AND “aging.” Searches were limited to reviews, meta-analyses, and controlled clinical trials in humans aged 45 years and older that were published in core clinical journals. A total of 26, 21, 230, and 139 articles were identified. Additional articles were identified by a review of references cited in these publications. In addition, searches of government web sites (National Institute on Aging [NIA], Agency for Healthcare Research and Quality [AHRQ], and Food and Drug Administration [FDA]), the Institute of Medicine (IOM) web site, and selected medical specialty society web sites (American Association of Clinical Endocrinologists [AACE], Endocrine Society, American Geriatrics Society, and American College of Obstetricians and Gynecologists [ACOG]) were conducted to identify clinical guidelines and position statements.

Results: Based on an AHRQ-funded systematic review and a more recent randomized, controlled clinical trial, current evidence fails to support the efficacy of hGH as an antiaging therapy and adverse events are significant. A review of 11 randomized, placebo-controlled clinical trials indicates that the use of DHEA as an antiaging supplement shows neither meaningful benefit nor serious adverse events. Based on systematic reviews conducted by the IOM and the Endocrine Society, as well as the Council’s evaluation of seven more recent randomized, placebo-controlled clinical trials, definitive evidence of the value of testosterone as an antiaging therapy in older men does not exist, and further research is indicated. Estrogens with or without progestins are highly effective in treating the vasomotor symptoms associated with menopause. However, primarily based on the Women’s Health Initiative (WHI), a large, randomized, placebo-controlled, primary (chronic condition) prevention clinical trial in postmenopausal women, the long-term use of estrogens with or without progestins causes more risks than benefits in this population. No credible scientific evidence exists on the value of so-called “bioidentical hormones,” and there are concerns about their purity, potency and quality because they are not approved by the FDA.

Conclusion: Despite the widespread promotion of hormones as antiaging agents by for-profit web sites, antiaging clinics, and compounding pharmacies, the scientific evidence to support these claims is lacking. The use of hGH and DHEA as antiaging agents is not recommended. Similarly, the long-term use of estrogens with or without progestins for the prevention of chronic conditions in postmenopausal women is not recommended. Considerable research has been conducted on testosterone in older men, but current evidence does not support its use in all older men with low testosterone levels. Physicians should consider offering testosterone therapy on an individualized basis to older men with consistently low testosterone levels on more than one occasion and clinically significant symptoms of androgen deficiency, after explicit discussion of the uncertainty about the risks and benefits of testosterone therapy. The IOM has defined a research agenda for the study of testosterone therapy in older men and this agenda should be followed.

REPORT OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH

CSAPH Report 5-A-09

Subject: The Use of Hormones for “Antiaging”: A Review of Efficacy and Safety

Presented by: Carolyn B. Robinowitz, MD, Chair

Referred to: Reference Committee E
(Martin G. Guerrero, MD, Chair)

1 A Google search of the term, “antiaging,” resulted in more than 34 million hits on January 12,
2 2009. Many of the highest ranked listings were for-profit web sites, antiaging clinics, and
3 compounding pharmacies that promoted a plethora of products, including hormones, antioxidants,
4 vitamins, herbal supplements, and other substances, as proven treatments to prevent, slow, or
5 reverse age-related changes in otherwise healthy adults. It is estimated that the United States
6 market for antiaging products is around \$50 billion annually.^{1,2}

7
8 Our American Medical Association’s (AMA) House of Delegates has raised questions and
9 concerns about the benefits and risks of medications and other substances touted to be
10 “antiaging,” and adopted Resolution 501 at the 2008 Annual Meeting (Directive D-100.979,
11 AMA Policy Database). This resolution asks:

12
13 That our AMA Council on Science and Public Health (CSAPH) undertake a review of
14 “anti-aging” medications, their efficacy, benefits, and risks, and report back to the
15 House of Delegates.

16
17 The number of medications and other substances being promoted as “antiaging” is vast, and the
18 Council believes it is impossible to consider them all in a single report. Therefore, this report will
19 focus on the use of hormones that have been promoted for antiaging. The report will review the
20 scientific evidence on the benefits and risks of human growth hormone (hGH),
21 dehydroepiandrosterone (DHEA), testosterone, and estrogens with or without progestins as
22 supplements to prevent, slow, or reverse age-related changes in otherwise healthy adults.

23
24 **AMA POLICY**

25
26 Currently, the AMA has no policy on antiaging. Directive D-120.969 (AMA Policy Database)
27 calls for Food and Drug Administration (FDA) oversight of “bioidentical hormone” (BH)
28 preparations.

29
30 **METHODS**

31
32 Four MEDLINE searches were conducted using the MESH terms “human growth hormone”
33 AND “aging,” “dehydroepiandrosterone” AND “aging,” “testosterone” AND “aging,” and
34 “estrogens” AND “aging.” Searches were limited to reviews, meta-analyses, and controlled
35 clinical trials in humans aged 45 years and older that were published in core clinical journals. A
36 total of 26, 21, 230, and 139 articles were identified, respectively. Additional articles were

1 identified by a review of references cited in these publications. In addition, searches of
2 government web sites (National Institute on Aging [NIA], Agency for Healthcare Research and
3 Quality [AHRQ], and FDA), the Institute of Medicine (IOM) web site, and selected medical
4 specialty society web sites (American Association of Clinical Endocrinologists [AACE],
5 Endocrine Society, American Geriatrics Society, and American College of Obstetricians and
6 Gynecologists [ACOG]) were conducted to identify clinical guidelines and position statements.

7 8 RESULTS

9 10 *Human Growth Hormone (hGH)*

11
12 Growth hormone, a protein hormone produced by the anterior pituitary gland, reaches maximal
13 secretion in adolescence and then decreases in an age-related manner in adulthood.³ Replacement
14 therapy in adults with FDA-approved recombinant human growth hormone is indicated for adults
15 with adult-onset growth hormone deficiency (GHD) as a result of pituitary disease, hypothalamic
16 disease, surgery, radiation therapy, or trauma; or for adults who had childhood-onset GHD as a
17 result of congenital, genetic, acquired, or idiopathic causes. In both instances, confirmation of the
18 diagnosis of adult GHD requires an appropriate growth hormone stimulation test to justify hGH
19 therapy except in cases of congenital/genetic GHD or multiple pituitary hormone deficiencies.
20 Adult GHD is very rare (approximately three cases per 10,000 adults).⁴ However, despite the
21 limited approved indications, hGH is widely used as an antiaging therapy in otherwise healthy
22 individuals.^{4,5}

23
24 Under a grant from the AHRQ, Liu and colleagues performed a systematic review of the
25 published literature through November 2005 to evaluate the safety and efficacy of hGH, injected
26 subcutaneously, in the healthy elderly. The authors only included randomized, controlled trials
27 that compared hGH therapy (with or without lifestyle interventions) with no hGH therapy for two
28 weeks or longer in community-dwelling men and women with a mean age of 50 years or more
29 and a body mass index (BMI) of 35 kg/m² or less. Thirty-one articles describing 18 unique study
30 populations were included, but only 220 total participants completed the studies. Initial hGH
31 dose (mean, 14 ug/kg/day; range, 1.7 to 43 ug/kg/day), final hGH dose (mean, 11.2 ug/kg/day;
32 range, 1.7 to 25 ug/kg/day), and study duration (mean 26.6 weeks; range, 2 to 52 weeks) varied
33 widely across studies. No study was longer than one year in duration. Therapy with hGH
34 produced small changes in body composition, i.e., increased lean body mass and decreased fat
35 body mass, but selection bias could not be ruled out. However, hGH therapy failed to improve
36 other clinically important outcomes, such as maximal oxygen consumption, bone mineral density,
37 lipid levels, and fasting glucose and insulin levels. Of particular importance, persons receiving
38 hGH experienced significantly higher rates of adverse events, including soft tissue edema,
39 arthralgias, carpal tunnel syndrome, and gynecomastia, and were somewhat more likely to
40 experience the onset of diabetes mellitus and impaired fasting glucose. The authors concluded
41 that the published literature, albeit limited, failed to support the use of hGH as an antiaging
42 therapy and recommended against such use.⁵

43
44 The CSAPH's literature review identified only one additional randomized, controlled trial that
45 was conducted after the systematic review described above. Giannoulis et al compared hGH
46 (initial dose, 0.1 mg/day by subcutaneous injection) to placebo (and also to testosterone with or
47 without hGH) in 80 healthy, community-dwelling men aged 65 to 80 years over a period of six
48 months. Twenty patients were in the placebo arm and 18 patients were in the hGH arm of the
49 study. While hGH modestly increased lean body mass, it had no effect on fat body mass, muscle
50 strength, or maximal oxygen consumption. Forty-one percent of individuals receiving hGH had

1 adverse events, but most were mild.⁶ This study failed to add any new information that would
2 support the use of hGH as an antiaging therapy.

3 Based on the available scientific evidence, the FDA, Endocrine Society, and AACE have taken
4 positions that there is no justifiable reason to use hGH for antiaging.⁷⁻⁹ Furthermore, the Food,
5 Drug and Cosmetic Act (FDCA) prohibits the distribution of hGH for any use in humans other
6 than for the treatment of a disease or other recognized medical condition, where such use has
7 been authorized by the Secretary of Health and Human Services under section 505 [of the FDCA]
8 and pursuant to an order of a physician. Violation of this provision of the FDCA can result in up
9 to five years in prison and substantial fines.¹⁰

10 *Dehydroepiandrosterone (DHEA)*

11
12
13 DHEA is produced by the adrenal gland and is released into the circulation as a water-soluble,
14 sulfate conjugated form (DHEAS). DHEA is a metabolic intermediate in the pathway for the
15 synthesis of testosterone, estrone, and estradiol. With age, levels of DHEA and DHEAS in both
16 sexes decrease at a relatively constant rate of 2% per year; hence at age 80 years, levels are only
17 about 20% of those at age 20 years. The administration of exogenous DHEA has been widely
18 promoted to prevent, slow, or reverse age-related changes in otherwise healthy adults.¹¹

19
20 Eleven randomized, placebo-controlled clinical trials assessing the efficacy and safety of DHEA
21 as an antiaging supplement were identified and summaries of these clinical trials are presented in
22 the Table. Studies were conducted in both men and women, primarily those over 55 years of age
23 (age range, 40-80 years). The most common daily dose of DHEA, administered orally, was 50
24 mg (range 50 mg-1,600 mg); most studies were from 6 months to 1 year in duration (range, 28
25 days to 2 years). The two most common outcomes measured were changes in bone mineral
26 density (BMD) and changes in body composition. Some studies also assessed muscle strength,
27 physical performance, quality of life, and effect on libido.

28
29 In some studies, DHEA resulted in increases, albeit small increases, in BMD in specific bones
30 and this occurred more frequently in elderly women.^{12-14,19} However, these inconsistent increases
31 in BMD were considerably less than what has been observed with current osteoporosis therapies,
32 such as the bisphosphonates, and there is no evidence that DHEA has any effect on reducing
33 fractures.²³ Almost all studies observed no effect of DHEA on body composition, i.e., reduced
34 BMI or fat mass or increased fat-free mass.^{12-15,17,20-22} DHEA also failed to increase muscle
35 strength,^{13,17} physical performance,¹³ quality of life,^{13,20} or to reduce the negative effects of
36 physical frailty.¹⁵ Effects on libido were inconsistent.¹⁹⁻²¹ Significant differences in adverse
37 events (e.g., increases in prostate specific antigen [PSA]) associated with DHEA therapy versus
38 placebo were not observed in these studies. However, because only one study was carried out
39 beyond one year, the safety of prolonged therapy with DHEA remains unknown.

40
41 Based on the available scientific evidence, the use of DHEA demonstrates neither meaningful
42 benefit nor adverse events, and its use as an antiaging supplement should be discouraged.
43 Unfortunately, DHEA currently is regulated as a dietary supplement in the United States and it is
44 widely available for over-the-counter sale with no restrictions on its use.²³ The NIA does not
45 recommend taking any dietary supplement touted as an “antiaging” remedy because there is no
46 proof of benefit and risks are unknown.²⁴

47 *Testosterone*

48
49
50 Endogenous testosterone, produced by the Leydig cells of the testes in males, is the principal
51 circulating androgen in males. Testosterone produces physiologic effects that are related to male

1 sexual differentiation, including urogenital development, increased libido, increased muscle mass
2 and strength, and increased bone mass. Endogenous serum testosterone levels peak in early
3 adulthood and then decline with aging. Exogenous testosterone therapy is clearly indicated for
4 men with hypogonadism. However, there is concern over the widespread promotion and use of
5 exogenous testosterone by middle-aged and older men with borderline – or even normal –
6 testosterone levels as an antiaging therapy.^{24,25}

7
8 In response to a request from the NIA and the National Cancer Institute in 2002, the IOM
9 systematically reviewed and assessed the current state of knowledge on the benefits and potential
10 risks of testosterone therapy in older men who did not meet the clinical diagnostic criteria for
11 hypogonadism. In addition, the IOM made recommendations regarding future clinical trials of
12 testosterone therapy in this population.²⁵

13
14 In its review, the IOM identified 31 randomized placebo-controlled clinical trials of testosterone
15 therapy in older men. Most of these clinical trials were of short duration (with only three studies
16 lasting 12 months or longer) and involved a small number of participants (only six studies
17 included 50 or more participants and only one clinical trial had more than 100 participants).
18 Types of testosterone and routes of administration (e.g., intramuscular, transdermal) varied across
19 studies. Most of the placebo-controlled clinical trials used doses of testosterone that raised serum
20 testosterone levels to the normal physiologic range for young adult males.²⁵

21
22 Based on its systematic review of the literature, the IOM found no clear evidence of benefit for
23 any of the health outcomes examined. For several health outcomes, results of these clinical trials
24 suggested a potential benefit from testosterone therapy. These areas – including beneficial effects
25 on body composition, strength, bone density, frailty, cognitive function, mood, sexual function,
26 and quality of life – require further study. Testosterone treatment consistently increased
27 hematocrit, but definitive evidence of other risks, such as increased prostate hyperplasia or
28 prostate cancer, were not observed. However, the size and length of the studies were inadequate
29 to really assess such risks.²⁵

30
31 The IOM concluded that the available clinical research on testosterone therapy in older men in
32 2003 produced only suggestions of benefit and potential risks, but little definitive evidence.
33 Therefore, the IOM recommended a research agenda to study testosterone in older men who
34 would be most likely to benefit. The IOM emphasized that testosterone, because of its potential
35 risks, should be studied as a therapeutic intervention and not be considered as a preventive
36 measure. Initially, the focus should be on conducting additional well-designed, randomized,
37 placebo-controlled trials to determine whether testosterone therapy provided any clear benefit in
38 any of the areas noted in the preceding paragraph. The IOM cautioned that large, long-term
39 studies to better assess risk should not be pursued until efficacy had clearly been shown.²⁵

40
41 In 2006, the Endocrine Society conducted a systematic review of the scientific evidence to
42 develop a clinical practice guideline on testosterone therapy in adult men with androgen
43 deficiency syndromes. A section of this clinical practice guideline focused on testosterone
44 therapy in older men with low serum testosterone concentrations. The clinical trials that were
45 identified and reviewed primarily included healthy older men with low or low-normal
46 testosterone levels and who were asymptomatic. Similar to what was found by the IOM, these
47 clinical trials were characterized by small sample size and the use of surrogate outcomes. The
48 studies lacked sufficient power to detect either meaningful gains in patient-important outcomes or
49 changes in prostate or cardiovascular event rates.²⁶

1 The Endocrine Society's review of the literature resulted in the following findings: 1) the effect
2 of testosterone on BMD yielded inconsistent and imprecise results and none of the studies
3 assessed the effect of testosterone on bone fractures; 2) testosterone therapy was significantly
4 associated with increased lean body mass and reduced fat mass; 3) testosterone was associated
5 with greater improvement of grip strength, but changes in lower-extremity muscle strength and
6 measures of physical function were inconsistent; 4) two placebo-controlled clinical trials on the
7 effect of testosterone on sexual function yielded imprecise results; 5) results of testosterone
8 therapy on quality-of-life were inconsistent; 6) testosterone had no effect on depression in older
9 men; and 7) results of clinical trials on cognition reported imprecise effects with no finding
10 achieving statistical significance after the studies were pooled. Based on a review of 19
11 randomized clinical trials for adverse events associated with testosterone therapy in older men,
12 the combined rate of prostate events (e.g., prostate cancer, PSA > 4 ng/ml, prostate biopsies) was
13 significantly greater in the testosterone group, but differences between testosterone and placebo
14 for any individual event failed to achieve statistical significance. Testosterone-treated men were
15 nearly four times more likely than placebo-treated men to experience hematocrits greater than
16 50%. No statistical differences were found for cardiovascular events, sleep apnea, or death
17 between groups.²⁶

18
19 The Endocrine Society recommended against offering testosterone therapy to all older men with
20 low testosterone levels. This was a strong recommendation, but one based on very low quality
21 evidence. The clinical practice guideline also suggested that physicians should consider offering
22 testosterone therapy on an individualized basis to older men with consistently low testosterone
23 levels on more than one occasion and clinically significant symptoms of androgen deficiency,
24 after explicit discussion of the uncertainty about the risks and benefits of testosterone therapy.
25 This was considered a weak recommendation, also based on very low quality evidence.²⁶

26
27 The CSAPH identified five additional randomized, placebo controlled trials, published from 2006
28 to 2008, that evaluated the effects of testosterone in healthy, community-dwelling elderly men
29 (age range, 55-85 years) with low serum testosterone levels.^{6,13,27-29} Between 43 and 70 older
30 men were included in four studies,^{6,13,28-29} and one study included more than 200 subjects.²⁷ The
31 testosterone dose was 5 mg/day, administered by transdermal patch, in four studies^{6,13,28-29};
32 testosterone undecenoate, administered orally in a dosage of 80 mg twice daily, was used in the
33 fifth study.²⁷ The durations of the studies were 2 years,¹³ 1 year,²⁸ 6 months,^{6,27} and 12 weeks.²⁹
34 Study outcomes varied, but included body composition,^{6,13,27-29} muscle strength,^{6,13,27} aerobic
35 capacity,^{6,13} BMD,¹³ cognition,²⁷ and quality of life.^{6,13,26} Testosterone was associated with
36 increased lean body mass and decreased fat mass in three studies,^{13,27,28} but there was no effect on
37 body composition in the other two clinical trials.^{6,29} In one study, an increase in BMD only in the
38 femoral neck (but not in any other bones) was noted in the testosterone group.¹³ There was no
39 effect of testosterone observed on muscle strength,^{6,13,27} aerobic capacity,^{6,13} cognition,²⁷ or
40 quality of life.^{6,13,27} In one study, quality of life, based on answers to the short form (SF)-36
41 questionnaire, improved only if testosterone was combined with an exercise program.²⁹ Serious
42 adverse events associated with testosterone generally were not observed in these studies. None of
43 these more recent clinical trials would alter the conclusions drawn by the IOM or the Endocrine
44 Society.

45
46 Bhasin and colleagues conducted a randomized, double-blind, placebo-controlled trial to examine
47 the anabolic effects of graded doses of testosterone (25-600 mg, administered intramuscularly,
48 weekly for 20 weeks) on skeletal muscle in healthy, older men (n = 60) aged 60 to 75 years.
49 Subjects also received a monthly injection of a long-acting GnRH agonist (Lupron depot, 7.5 mg)
50 to suppress endogenous testosterone production. Testosterone was associated with significant
51 dose-dependent increases in skeletal muscle mass and maximal strength, but the frequency of

1 serious adverse events (hematocrit > 54%, leg edema, prostate events) also increased with dose.³⁰
2 Interestingly, despite the increased skeletal muscle mass and strength, testosterone had no effect
3 on muscle fatigability or on various tests of physical function (stair climb, timed up-and-go,
4 walking speed) in this population. The authors believed that physical function did not improve
5 because these high-functioning older men were already in the asymptotic region of the curve
6 describing the relationship between physical function and strength. Thus, the authors suggested
7 that future clinical trials of testosterone should be conducted in older individuals who have more
8 functional limitations. However, the authors also cautioned that the potential for serious adverse
9 events in older men at higher doses of testosterone could temper its potential application as a
10 function-promoting therapy.³¹

11
12 Information on the use of testosterone as an antiaging therapy in women is extremely limited.
13 The North American Menopause Society (NAMS) conducted an evidence-based review of
14 testosterone therapy in postmenopausal women and identified a few randomized, controlled
15 clinical trials that indicated exogenous testosterone, both in oral and nonoral formulations, has a
16 positive effect on sexual function, primarily desire, arousal, and orgasmic response, in women
17 after spontaneous or surgically induced menopause. In all of the clinical trials, estrogen (with or
18 without progestin) was administered concomitantly and all of the studies were of short duration
19 (≤ 6 months). Data were insufficient to determine whether testosterone had an effect on
20 increasing BMD, reducing hot flashes, increasing lean body mass, or improving well-being in
21 women who participated in these studies. Side effects included hirsutism and acne. NAMS
22 concluded that postmenopausal women with decreased sexual desire associated with personal
23 distress and with no other identifiable cause may be candidates for a short course of low dose
24 testosterone therapy with concomitant estrogen, but only after a comprehensive clinical
25 evaluation.³²

26
27 A more recent long-term, randomized, placebo-controlled, multicenter clinical trial assessed the
28 efficacy and safety of a testosterone patch at a dose of either 300 ug per day or 150 ug per day in
29 814 women with low sexual desire and who were either naturally or surgically menopausal and
30 not taking estrogen or progesterone. Efficacy was measured to week 24; safety was evaluated
31 over a period of 52 weeks, with a subgroup of participants followed for an additional year. The
32 primary endpoint was the change from baseline to week 24 in the 4-week frequency of satisfying
33 sexual episodes. At 24 weeks, the increase in the 4-week frequency of satisfying sexual episodes
34 was significantly greater in the group receiving 300 ug of testosterone per day versus the placebo
35 group, but not in the group receiving 150 ug of testosterone per day. Both doses of testosterone,
36 however, were associated with significant increases in sexual desire and decreases in distress.
37 The rate of androgenic adverse events – primarily unwanted hair growth – was higher in the
38 group receiving 300 ug of testosterone versus placebo. Breast cancer was diagnosed in four
39 women who received testosterone, but in no women receiving placebo.³³ While this study
40 confirms the potential value of testosterone – given without estrogen and/or progestin – as a
41 treatment for hypoactive sexual desire, the breast cancer findings suggest the need for caution in
42 the use of testosterone until the potential relationship to breast cancer is better understood.³⁴

43
44 Testosterone (and other anabolic steroids) are regulated by the Drug Enforcement Administration
45 (DEA) as Schedule III controlled substances, and can only be prescribed or dispensed for a
46 legitimate medical purpose in the usual course of professional practice.³⁵

47 *Estrogens With or Without Progestins*

48
49
50 The Women's Health Initiative (WHI) was a large, randomized, placebo-controlled, primary
51 prevention clinical trial whose goal was to define the risks and benefits of estrogen plus progestin,

1 or estrogen alone (in women with hysterectomy), in postmenopausal women. Postmenopausal
2 women, aged 50 to 79 years, with an intact uterus received either conjugated equine estrogens
3 (CEE) (0.625 mg/day) plus medroxyprogesterone acetate (MPA) (2.5 mg/day) [n = 8506] or
4 placebo [n = 8102]. Postmenopausal women, aged 50 to 79 years, with prior hysterectomy
5 received either CEE (0.625 mg/day) [n = 5310] or placebo [n = 5429]. The WHI estrogen plus
6 progestin trial was terminated early at an average of 5.2 years of follow-up because health risks
7 exceeded benefits.³⁶ The WHI estrogen-only trial also was terminated early after an average of
8 6.8 years of follow-up.³⁷

9
10 The WHI study found some benefits of CEE plus MPA in reducing the risk for fracture and
11 colorectal cancer.³⁶ However, combined therapy increased the risk of breast cancer,³⁶ venous
12 thromboembolism,³⁶ stroke,³⁶ dementia,³⁸ and lower global cognitive function.³⁹ Initial results of
13 the WHI study for the entire population suggested that CEE plus MPA also increased the risk of
14 coronary heart disease (CHD),³⁶ but further analysis of the data suggested women who initiated
15 hormone therapy closer to menopause tended to have reduced CHD risk compared with an
16 increase in CHD risk among women more distant to menopause.⁴⁰

17
18 Estrogen, used alone in postmenopausal women with hysterectomy, also reduced the risk of
19 fractures,³⁷ but increased the risk of stroke,³⁷ venous thromboembolism,³⁷ dementia,³⁸ and lower
20 global cognitive function.³⁹ No effect on the incidences of CHD,³⁷ breast cancer,⁴¹ or colorectal
21 cancer³⁷ were observed. Further analysis of the data suggested women who received CEE
22 therapy closer to menopause tended to have a reduced CHD risk,⁴⁰ and an ancillary substudy of
23 the WHI showed that CEE reduced the calcified-plaque burden in the coronary arteries of women
24 aged 50 to 59 years when compared to placebo.⁴² The AACE and NAMS have taken positions
25 that additional, randomized clinical trials are necessary in younger women who are closer to
26 menopause to more clearly determine the effects of estrogen with or without progestin on CHD
27 risk in this population.^{43,44}

28
29 Based primarily on the results of the WHI clinical trial, as well as other studies,^{45,46} the U.S.
30 Preventive Services Task Force (USPSTF) recommends against the routine use of combined
31 estrogen plus progestin for the prevention of chronic conditions in postmenopausal women.⁴⁷
32 The USPSTF also recommends against the routine use of estrogen alone for the prevention of
33 chronic conditions in postmenopausal women who have had a hysterectomy.⁴⁷ The FDA also
34 requires estrogen/progestin or estrogen-only products to contain a black box warning regarding
35 potential serious adverse events with long-term administration.^{48,49}

36
37 Estrogens alone or estrogens plus progestins are highly effective for alleviating the vasomotor
38 symptoms (hot flashes, night sweats) associated with menopause,^{44,50-52} and have FDA-approved
39 labeling for this indication.^{48,49} Currently, the FDA and ACOG's Committee on Gynecologic
40 Practice recommend that estrogen or estrogen plus progestin therapy be limited to the treatment
41 of menopausal symptoms at the lowest effective dosage over the shortest duration possible, and
42 continued use should be reevaluated on a periodic basis.^{48,49,53} The AACE also has a position
43 statement supporting the use of estrogen (or estrogen plus progestin) for the relief of menopausal
44 symptoms, and recommends that each patient be evaluated for severity of symptoms, age, and
45 specific risk factors and receive appropriate counseling from her physician.⁴³ Estrogens alone or
46 estrogens plus progestins also are effective for treating the symptoms of vulvar and vaginal
47 atrophy associated with menopause, but topical administration is preferred.^{48,49}

48
49 In light of the WHI findings, numerous web sites, books, and antiaging clinics that promote the
50 use of hormones for antiaging are touting the use of so-called "bioidentical hormones" (also
51 called natural hormones) as superior in efficacy and safety to estrogen or estrogen-progestin drug

1 products that are approved by the FDA. The term “bioidentical hormones” is quite vague, and is
2 used in various contexts. Most commonly, this term denotes hormones that are derived from
3 plants (e.g., soy or yams) and custom compounded for patients by pharmacists. These steroids
4 may include estrone, estradiol, estriol, and progesterone. However, reliable clinical trial data on
5 the benefits and adverse effects of compounded bioidentical hormones are essentially
6 nonexistent.^{24,51} The FDA, ACOG, AACE and the Endocrine Society have all taken the position
7 that, absent evidence to the contrary, all estrogen-containing hormone therapies, whether
8 bioidentical or traditional FDA-approved, carry essentially the same risks and benefits.^{48,49,54-56}
9 Thus, claims of superior efficacy and safety for bioidentical hormones are unfounded, and the
10 FDA has issued warning letters to compounding pharmacies that have made such claims.⁵⁷
11 Compounded bioidentical hormones carry additional concerns about efficacy, safety, purity,
12 potency, and quality because they have not undergone the rigorous FDA approval process.^{44,54-56}
13 As discussed above, current AMA Directive D-120.969 calls for FDA oversight of bioidentical
14 hormone preparations.

15 16 CONCLUSION

17
18 Despite the widespread promotion of hormones as antiaging agents by for-profit web sites,
19 antiaging clinics, and compounding pharmacies, the scientific evidence to support these claims is
20 lacking. In some cases, the evidence suggests long-term use of a particular hormone can present
21 more risks than benefits. Based on current evidence, this clearly is the case for hGH.

22
23 A number of randomized, placebo-controlled clinical trials have evaluated DHEA as an antiaging
24 agent and essentially all were negative. While adverse events associated with DHEA in these
25 clinical trials were minimal, the long-term safety of this dietary supplement could not be
26 determined. The regulatory status of this hormone as a dietary supplement allows it to be
27 available over-the-counter and this raises additional concerns. The NIA does not recommend
28 taking any dietary supplement touted as an “antiaging” remedy because there is no proof of
29 benefit and risks are unknown.²⁴

30
31 Considerable research has been conducted on testosterone in older men, but current evidence does
32 not support its use in all older men with low testosterone levels. The Endocrine Society suggests
33 that physicians should consider offering testosterone therapy on an individualized basis to older
34 men with consistently low testosterone levels on more than one occasion and clinically significant
35 symptoms of androgen deficiency, after explicit discussion of the uncertainty about the risks and
36 benefits of testosterone therapy. This was considered a weak recommendation, and one based on
37 very low quality evidence.²⁶ The IOM has defined a research agenda for the study of
38 testosterone therapy in older men and this agenda should be followed.

39
40 While estrogens with or without progestins are indicated for women with menopausal symptoms,
41 the long-term use of estrogens with or without progestins for the prevention of chronic conditions
42 in postmenopausal women is not recommended. There is no credible evidence to support claims
43 of for-profit web sites, anti-aging clinics, and compounding pharmacies that so-called bioidentical
44 hormones have superior efficacy and safety over traditional FDA-approved estrogen or
45 estrogen/progestin drug products. Because compounded bioidentical hormones are not subject to
46 the FDA approval process, additional concerns exist about their purity, potency, and quality.

1 RECOMMENDATIONS

2

3 The Council on Science and Public Health recommends that the following recommendations be
4 adopted and that the remainder of this report be filed:

5

6 1. That our American Medical Association widely disseminate this report to inform physicians,
7 policy makers, and the public of the current scientific evidence on the use of hormones as
8 antiaging agents. (Directive to Take Action)

9

10 2. That our AMA take the position that proponents of any hormone or other substance as an
11 antiaging agent have the responsibility to prove that any claims of positive benefit/risk be
12 supported by well-designed, randomized, placebo-controlled clinical trials. (New HOD
13 Policy)

14

15 3. That Directive D-100.979 be rescinded because it has been effected.

Fiscal Note: \$1,000

REFERENCES

1. Wilson D. Aging: disease or business opportunity? *New York Times*. April 15, 2007. <http://www.nytimes.com/2007/04/15/business/yourmoney/15aging.html>. Accessed March 10, 2009.
2. Weintraub A. Selling the promise of youth. *BusinessWeek*. March 20, 2006. http://www.businessweek.com/magazine/content/06_12/b3976001.htm. Accessed March 10, 2009.
3. Parker KL, Schimmer BP. Pituitary hormones and their hypothalamic releasing factors. In: Hardman JG, Limbird LE, Gilman AG, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 10th ed. New York, NY: McGraw-Hill; 2001:1541-1562.
4. Olshansky SJ, Perls TT. New developments in the illegal provision of growth hormone for "anti-aging" and bodybuilding. *JAMA*. 2008;299:2792-2794.
5. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. *Ann Intern Med*. 2007;146:104-115.
6. Giannoulis MG, Sonksen PH, Umpleby M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. *J Clin Endocrinol Metab*. 2006;91:477-484.
7. Perls TH, Reisman NR, Olshansky SJ. Provision or distribution of growth hormone for "antiaging": clinical and legal issues. *JAMA*. 2005;294:2086-2090.
8. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee of the Clinical Affairs Committee. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2006;91(5):1621-1634. <http://jcem.endojournals.org/cgi/reprint/91/5/1621?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=molitch&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=91&firstpage=1621&resourcetype=HWCIT>. Accessed January 19, 2009.
9. American Association of Clinical Endocrinologists Growth Hormone Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update. *Endocr Pract*. 2003;9(1):64-76. <http://www.aace.com/pub/pdf/guidelines/hgh.pdf>. Accessed January 19, 2009.
10. 21USC333(e).
11. Horani MH, Morley JE. Hormonal fountains of youth. *Clin Geriatr Med*. 2004;20:275-292.
12. von Muhlen D, Laughlin GA, Kritz-Silverstein D, et al. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. *Osteoporos Int*. 2008;19:699-707.
13. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. *N Engl J Med*. 2006;355:1647-1659.

14. Jankowski CM, Gozansky WS, Schwartz RS, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. *J Clin Endocrinol Metab.* 2006;91:2986-2993.
15. Muller M, van den Beld AW, van der Schouw YT, et al. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. *J Clin Endocrinol Metab.* 2006;91:3988-3991.
16. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. *JAMA.* 2004;292:2243-2248.
17. Percheron G, Hogrel J, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. *Arch Intern Med.* 2003;163:720-727.
18. Kahn AJ, Halloran B. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men. *J Clin Endocrinol Metab.* 2002;87:1544-1549.
19. Baulieu E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociomedical issue. *PNAS.* 2000;97:4279-4284.
20. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans. *J Clin Endocrinol Metab.* 1999;84:1527-1533.
21. Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Clin Endocrinol Metab.* 1994;78:1360-1367.
22. Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. *J Clin Endocrinol Metab.* 1990;71:696-704.
23. Stewart PM. Aging and fountain-of-youth hormones. *N Engl J Med.* 2006;355:1724-1726.
24. National Institute on Aging. Tips from the National Institute on Aging: Can we prevent aging? <http://www.nia.nih.gov/HealthInformation/Publications/preventaging.htm>. Accessed January 21, 2009.
25. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy, Institute of Medicine. *Testosterone and Aging: Clinical Research Directions.* Washington, DC: National Academies Press; 2003.
26. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Endocrine Society's Androgen Deficiency Syndromes Task Force. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2006;91(6):1995-2010. <http://www.endo-society.org/guidelines/final/upload/AndrogensMenGuideline053006.pdf>. Accessed January 23, 2009.

27. Emmelot-Vonk MH, Verhaar HJJ, Pour HRN, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. *JAMA*. 2008;299:39-52.
28. Allan CA, Strauss BJG, Burger HG, et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. *J Clin Endocrinol Metab*. 2008;93:139-146.
29. Katznelson L, Robinson MW, Coyle CL, et al. Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men. *Eur J Endocrinol*. 2006;155:867-875.
30. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. *J Clin Endocrinol Metab*. 2005;90:678-688.
31. Storer TW, Woodhouse L, Magliano L, et al. Changes in muscle mass, muscle strength, and power, but not physical function are related to testosterone dose in healthy older men. *J Am Geriatr Soc*. 2008;56:1991-1999.
32. Position Statement. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. *Menopause*. 2005;12:497-511.
33. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. *N Engl J Med*. 2008;359:2005-2017.
34. Heiman JR. Treating low sexual desire – new findings for testosterone in women. *N Engl J Med*. 2008;359:2047-2049.
35. 21CFR1306.04 and 21CFR1308.13.
36. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. *JAMA*. 2002;288:321-333.
37. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. *JAMA*. 2004;291:1701-1712.
38. Schumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative memory study. *JAMA*. 2004;291:2947-2958.
39. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative memory study. *JAMA*. 2004;291:2959-2968.
40. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA*. 2007;297:1465-1477.

41. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA*. 2006;295:1647-1657.
42. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. *N Engl J Med*. 2007;356:2591-2602.
43. AACE Reproductive Medicine Committee. American Association of Clinical Endocrinologists (AACE) Position Statement on Hormone Replacement Therapy (HRT) and Cardiovascular Risk. http://www.aace.com/pub/pdf/guidelines/HRTCVRISKposition_statement.pdf. Accessed January 28, 2009.
44. Position Statement. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. *Menopause*. 2008;15:584-602.
45. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). *JAMA*. 2002;288:49-57.
46. Hulley S, Furberg C, Barrett-Conner E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). *JAMA*. 2002;288:58-66.
47. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. *Ann Intern Med*. 2005;142:855-860.
48. FDA-approved prescribing information for PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets). <http://www.wyeth.com/content/showlabeling.asp?id=133>. Accessed January 27, 2009.
49. FDA-approved prescribing information for PREMARIN (conjugated estrogens tablets, USP). <http://www.wyeth.com/content/showlabeling.asp?id=131>. Accessed January 27, 2009.
50. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. *JAMA*. 2004;291:1610-1620.
51. NIH State-of-the-Science Panel. National Institutes of Health State-of-the-Science Committee statement: management of menopause-related symptoms. *Ann Intern Med*. 2005;142:1003-1013.
52. ACOG Task Force on Hormone Therapy. Hormone therapy. *Obstet Gynecol*. 2004;104(4)(Supplement):1S-131S.
53. ACOG Committee on Gynecologic Practice. Hormone therapy and heart disease: ACOG Committee opinion. *Obstet Gynecol*. 2008;112:1189-1192.

54. ACOG Committee on Gynecologic Practice. Compounded bioidentical hormones: Committee Opinion. *Obstet Gynecol.* 2005;106:1139-1140.
55. AACE Reproductive Medicine Committee. American Association of Clinical Endocrinologists (AACE) Reproductive Medicine Committee Position Statement on Bioidentical Hormones, July 15, 2007. <http://www.aace.com/pub/pdf/guidelines/AACEBHStatement071507.pdf>. Accessed January 28, 2009.
56. The Endocrine Society. Position Statement: Bioidentical Hormones, October 2006. http://www.endo-society.org/advocacy/policy/upload/BH_position_Statement_final_10_25_06_w_Header.pdf. Accessed January 28, 2009.
57. FDA takes action against compounded menopause hormone therapy drugs. *FDA News*. January 9, 2008. <http://www.fda.gov/bbs/topics/NEWS/2008/NEW01772.html>. Accessed March 11, 2009.

TABLE: DEHYDROEPIANDROSTERONE AND ANTIAGING: SUMMARY OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS

<i>Study</i>	<i>Patient population</i>	<i>Daily dose (mg)</i>	<i>Duration of therapy</i>	<i>Effect on BMD^a</i>	<i>Effect on body composition^b</i>	<i>Other effects</i>
von Muhlen et al (2008) ¹²	225 healthy men and women; aged 55-85 years	50 po	1 year	Slight increase in spine BMD in women; all other measures negative	No effect	No serious AEs ^c
Nair et al (2006) ¹³	144 elderly men and women; aged ≥ 60 years	75 po	2 years	Slight increase in ultradistal radius BMD in women and femoral BMD in men; all other measures negative	No effect	No effect on physical performance ^e or quality of life ^f ; no serious AEs
Jankowski et al (2006) ¹⁴	140 men and women with low DHEA; aged 60-88 years	50 po	1 year	Increase in hip BMD and slight increase in spine BMD in women	No effect	Three serious AEs reported
Muller et al (2006) ¹⁵	100 men; aged ≥ 70 years	50 po	36 weeks	No effect	Increased BMI	No effect on physical frailty ^g
Villareal and Holloszy (2004) ¹⁶	56 elderly men and women; aged 65-78 years	50 po	6 months	Not studied	Decreases in abdominal visceral and subcutaneous fat	No serious AEs
Percheron et al (2003) ¹⁷	280 healthy men and women; aged 60-79 years ^d	50 po	1 year	Not studied	No effect	No effect on muscle strength ^h
Kahn and Halloran (2002) ¹⁸	43 healthy men; aged 56-80 years	90 po	6 months	No effect on bone turnover ⁱ	Not studied	

Table (continued)

<i>Study</i>	<i>Patient population</i>	<i>Daily dose (mg)</i>	<i>Duration of therapy</i>	<i>Effect on BMD^l</i>	<i>Effect on body composition²</i>	<i>Other effects</i>
Baullieu et al (2000) ¹⁹	280 healthy men and women; aged 60-79 years ^d	50 po	1 year	Bone turnover slightly improved only in women > 70 ^j	Not studied	Increase in libido in women >70 ^k and some improvement in skin ^l ; no serious AEs
Flynn et al (1999) ²⁰	39 healthy men; aged 60-84 years	100 po (50 mg bid)	3 months	Not studied	No effect	No effect on sense of well being or on libido ^m
Morales et al (1994) ²¹	30 men and women; aged 40-70 years	50 po	3 months	Not studied	No effect	Increased sense of well being but no effect on libido ⁿ ; no serious AEs
Mortola and Yen (1990) ²²	6 postmenopausal women	1600 po (400 mg qid)	28 days	Not studied	No effect	No serious AEs

^aBMD is bone mineral density.

^bMeasures of body composition varied across studies, and included lean body mass, abdominal fat mass, lean/fat index, total fat mass, BMI and waist to hip ratio.

^cAEs are adverse events associated with dehydroepiandrosterone.

^dThe populations studied in these two publications were the same.

^ePeak VO₂ and changes in muscle strength were measures of physical performance.

^fChanges in scores on the Physical Component Scale and Mental Component Scale of the Health Status Questionnaire were measures of quality of life.

^gTests to measure physical frailty included isometric grip strength, leg extensor power, standing balance, walking speed, and ability to rise from chair.

^hMeasures of muscle strength included handgrip strength and knee muscle strength.

ⁱMeasures of bone turnover included serum measurements of procollagen peptide, bone-specific alkaline phosphatase, and deoxypyridinoline.

^jMeasures of bone turnover included dual energy x-ray absorptiometry (DEXA) technique and decrease of osteoclastic activity.

^kBased on a questionnaire.

^lMeasurements included sebum production, skin hydration, and skin pigmentation.

^mBased on a questionnaire.

ⁿSense of well being was assessed by an open-ended questionnaire, and libido was assessed by a visual analog scale.